Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 1998

View Archived Issues

Basis of beneficial effects of cactus flower in BPH

Vitamin D analogue Ro-25-9716 potentially useful in treating myeloid leukemia

Kappa-opioid antagonist MR-2266 is also an antagonist of ORL1 receptors

Ibex to resume testing of heparin-reversing agent

Ajinomoto prepares extensive series with anticoagulant efficacy

Neuroprotective indolomorphinane derivatives under development at Toray

Camptothecin analogues and prodrugs described in patent literature by SCRAS

Novel vitamin D compounds claimed for use in bone disorders and psoriasis

Successful completion of phase I/II clinical trial of VIMRxyn in brain cancer

Genentech begins shipping Herceptin to U.S. oncologists

Oral insulin formulation developed at Generex headed for U.S. clinical trials

Japan Tobacco obtains rights to Terumo antiplatelet agent

UT-15 administered successfully to patients with impaired liver function

Nasally delivered flu vaccine safe and immunogenic in adults

Intranasal delivery of CpG DNA with HBsAg stimulates both systemic and mucosal immunity

HIV integrase inhibitors may impart greater efficacy to combination therapies

FDA Oncologic Drugs Advisory Committee meets for two days in November

FDA approves Nolvadex for prevention of breast cancer

New COX-2 inhibitor scheduled for FDA advisory committee review in early December

SKB seeks OTC status for penciclovir cream

New company formed by Asta Medica and Carter-Wallace

Cytogen and Berlex enter into copromotion agreement for Quadramet

Intravenous N-0923 associated with rapid onset and short-lasting antiparkinsonian effects

How does bradykinin receptor blockade affect responses to ACE inhibition?

Vertex and HMR initiate phase I clinical trial with HMR-3480/VX-740

SB and Corixa expand vaccine collaboration

BioStratum's Pyridorin effective for diabetic nephropathy

Tacrolimus may represent novel neurotrophic strategy for neurodegenerative disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...